Compare MIAX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIAX | XENE |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | Canada |
| Employees | N/A | 327 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 2025 | 2014 |
| Metric | MIAX | XENE |
|---|---|---|
| Price | $44.42 | $42.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $47.20 | ★ $54.09 |
| AVG Volume (30 Days) | 963.0K | ★ 1.0M |
| Earning Date | 02-22-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,318,535,000.00 | $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.86 | N/A |
| 52 Week Low | $28.63 | $26.74 |
| 52 Week High | $51.38 | $46.60 |
| Indicator | MIAX | XENE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.44 |
| Support Level | N/A | $39.29 |
| Resistance Level | N/A | $42.00 |
| Average True Range (ATR) | 0.00 | 2.01 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 50.63 |
Miami International Holdings Inc is a technology-driven leader in building and operating regulated financial marketplaces across multiple asset classes and geographies. Its MIAX Exchange marketplaces are enabled by its in-house built, proprietary technology. It maintains a broad portfolio of U.S. exchange and clearing licenses, in both securities and futures. The company operates markets across a diverse number of asset classes including options and cash equities as well as futures and options on futures.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.